Chromadex Overview
Is CDXC undervalued? Intrinsic value estimate stands at $-0.1.
Get informed when a big investor buys or sells
+ Follow$-0.10
Overvalued by 101.3% based on the discounted cash flow analysis.
Chromadex (CDXC) currently reports a DCF fair value of $-0.1. Use the charts on this page to explore Chromadex's DCF fair value history and peer comparisons.
Chromadex's discounted cash flow (DCF) fair value estimate is $-0.1, about 101.3% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $-0.1, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chromadex, and consider following CDXC for alerts when major investors trade the stock.
Chromadex is classified in the Healthcare sector. On DCF fair value, it currently shows $-0.1. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CDXC with unrelated industries.
